RSS   Newsletter   Contact   Advertise with us

Adverum Biotechnologies adds Richard N. Spivey to board

Share on Twitter Share on LinkedIn
Staff Writer | Menlo Park, Ca., USA | April 24, 2017
Richard N. SpiveyApril 24, 2017, Menlo Park, Ca., USA - Adverum Biotechnologies, a gene therapy company, announced the appointment of Richard N. Spivey to its board of directors.
Dr. Spivey will be the chairman of the nomination and governance committee and a member of the audit committee.

Dr. Spivey has significant experience in research and development at leading global pharmaceutical companies.

Dr. Spivey currently serves as a scientific advisor to the pharmaceutical industry.

From 2010 to 2015, he served as senior vice president of global regulatory affairs at Allergan, plc.

During his tenure, he was responsible for pharmaceuticals, including the approvals of Botox and Ozurdex, and medical devices.

From 2002 to 2010, Dr. Spivey worked with Meda AB after the acquisition of MedPointe Pharmaceuticals, serving as chief scientific officer and head of research and development for both.

Earlier in his career, he worked for Pharmacia Corporation (now Pfizer, Inc.), Schering-Plough Corporation (now Merck & Co.), Parke-Davis/Warner-Lambert (now Pfizer, Inc.), and Boots Pharmaceuticals, Inc.

Dr. Spivey earned a Ph.D. in Pharmacy Administration from the University of Minnesota and a Pharm.D. from the University of Southern California.

He also serves as a member of the board of directors of Inotek Pharmaceuticals, where he is chairman of the nominating and governance committee since 2015.